WooGene B&G Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
May 13, 2022 at 12:04 pm IST
Share
WooGene B&G Co., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported negative sales was KRW 0.00001 million. Net income was KRW 364.21 million compared to net loss of KRW 1,066.45 million a year ago. Basic earnings per share from continuing operations was KRW 13 compared to basic loss per share from continuing operations of KRW 38 a year ago. Basic earnings per share was KRW 13 compared to basic loss per share of KRW 38 a year ago.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
